Physician profile
Keith C Chang
NPI 1588703995
$7,646.23
in general payments reported to CMS, 2019-2025
26 companies · $2,186 in 2025
The $2,186 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $448 · 2021: $676 · 2022: $455 · 2023: $1,693 · 2024: $1,477 · 2025: $2,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,338 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,337.83 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,539.01 | 2023-2025 | Durysta, Vuity, Alphagan P |
| Alcon Vision LLC | $1,003.37 | 2022-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Bausch & Lomb Americas INC. | $614.88 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $589.22 | 2020-2023 | |
| Allergan, INC. | $542.80 | 2019-2021 | |
| Amgen INC. | $499.38 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $485.69 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $382.46 | 2022-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $316.04 | 2021-2023 | Tepezza |
| Harrow Eye, LLC | $277.62 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $247.08 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $240.00 | 2019-2020 | |
| Ivantis, INC | $160.33 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $156.00 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $105.76 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $101.92 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $68.30 | 2021 | |
| Stryker Corporation | $60.61 | 2024 | Stryker |
| Eyevance Pharmaceuticals LLC | $58.42 | 2020-2023 | Flarex |
| Dompe US, INC. | $53.29 | 2024-2025 | Oxervate |
| Shire North American Group INC | $41.16 | 2019 | |
| Thea Pharma INC. | $22.75 | 2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $22.51 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $22.20 | 2019 | |
| Astellas Pharma US INC | $19.53 | 2024 | Izervay |
| Tandem Diabetes Care, INC. | $15.90 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.